Skip to main content
Premium Trial:

Request an Annual Quote

TGen Wins $150K Grant for AML Studies

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – A researcher at the Translational Genomics Research Institute has received a $150,000 grant from the American Cancer Society to identify potential targets of value in fighting acute myeloid leukemia (AML).

James Bogenberger, a researcher in TGen's Leukemia Research Team, will use the three-year grant to fund studies that will identify therapeutic targets that sensitize AML to epigenetic therapies, TGen said on Wednesday.

AML is a malignancy in white blood cells that fight infections, and it is the most common and deadliest form of acute adult leukemia. Because AML is caused by a progression of multiple cellular processes, this TGen project will seek to identify targets that inhibit it in combination with drugs that are already approved by the Food and Drug Administration.

Bogenberger's research will search for genes that, when silenced, may be used to increase the potency of these available epigenetic therapies.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.